Institute of Research, both in Silver Spring, Maryland. This shows that humans exposed to more than 1,000 bites by infected, irradiated mosquitoes develop over 90% protection against subsequent challenges, and that this protection lasts for more than 10 months (S. L. Hoffman et al. J. Infect.Dis. 185, 1155 -1164 2002) .
But the logistical problems are formidable. "The barriers have seemed sufficiently daunting that no one has been willing to give it a try," says Thomas Richie, director of clinical trials at the Naval Medical Research Center Malaria Program in Silver Spring. "It's a long shot," says Adrian Hill, a malaria-vaccine expert at the University of Oxford, UK: "It's worth a try, although the odds are heavily stacked against him."
Hoffman says his work at Celera Genomics on the mosquito genome project helped to convince him that the obstacles could be overcome. He expects to raise $3 million for the project, including a $550,000 grant from the National Institutes of Health.
He will need to produce sufficient numbers of sporozoites, and to store them in a way that retains their ability to infect liver cells. A bite sporozoites, to ensure that enough living parasites make it to the liver. This is already achievable from one mosquito, says Robert Sauerwein,head of medical parasitology at the University of Nijmegen in the Netherlands, a collaborator of Hoffman's. So one mosquito could produce one vaccine dose.
This assumes that most sporozoites will survive and be immunogenic after storage. If not, many more will be needed.And although mosquitoes inject sporozoites into the blood -an efficient route to the liver -intravenous vaccine injection is not an option. Hoffman thinks that vaccination under the skin should be feasible. But the route to the liver would have to be unusually efficient for this to work.
Hoffman says that with his initial funding he will make sporozoites of clinical-trial quality. If he is successful, a vaccine could be quickly tested in humans in areas of Africa where malaria transmission is high.
The plan is the "best show in town" for malaria vaccines, Mosquito production mooted as fast track to malaria vaccine
